Elastographic Improvement of Vaginal Atrophy Treated by Erbium Yag Laser

Sponsor
Istanbul University - Cerrahpasa (IUC) (Other)
Overall Status
Recruiting
CT.gov ID
NCT06000202
Collaborator
(none)
40
2
2
4.7
20
4.3

Study Details

Study Description

Brief Summary

This study is a randomized controlled sham applied study. Its aim is to evaluate the efficacy of Er:YAG laser for the treatment of atrophic vaginitis in postmenopausal women.

In this study, demonstration of the efficacy of Er:YAG laser for the treatment of atrophic vaginitis in postmenopausal women is intended with Maturation Index (MI), vaginal pH measurement, Female Sexual Function Index (FSFI), Vaginal Health Index (VaHI), Visual Analogue Scale (VAS) and ultrasonographic elastography

Condition or Disease Intervention/Treatment Phase
  • Device: Fotona Dynamis Er:YAG Laser System
  • Device: Sham
N/A

Detailed Description

In the postmenopausal period, especially due to estrogen deficiency, vaginal atrophy occurs in the vulvo-vagina, lower urinary tract, pelvic floor muscles and endopelvic fascia. Vaginal dryness secondary to atrophy in genital organs, pain and tenderness especially during sexual intercourse, and decreased genital elasticity are the most common symptoms and signs during the postmenopausal period. With regard to the urinary system, frequent urination, feeling of urgency, recurrent urinary tract infections, organ prolapses-urethrocele, cystocele, urethral prolapse and stress or urge type urinary incontinence could be seen.These signs and symptoms were recognized in 2014 by the International Society for the Study of Women's Sexual Health (ISSWSH) and the North American Menopause Society (NAMS) under the main title OF "genito-urinary syndrome of menopause" (GSM). During the postmenopausal period, a detailed history should be taken, a complete physical examination should be performed, and various tests should be performed for the evaluation of GSM.

Laser is a treatment option for the genitourinary symptoms that could occur at the postmenopausal period. Laser can be applied to vulva by giving an external beam, or it can be applied intravaginally or directly to the urethra using vaginal and urethral cannula.

The smooth mode application of the Er:YAG laser ensures that the laser beam retains the heat it gives without ablation and penetrates deeper into the tissue. After laser application, thermomechanical and thermochemical effects occur in the tissue, respectively. It provides controlled thermal energy and causes shrinkage of the collagen fibrils in the vaginal epithelium and lamina propria. It also induces neocollagenesis, elastogenesis and neoangiogenesis by temperature change. With minimum damage to the peripheral tissue, the viable cells in the target tissue reacts to this temperature change by expressing heat shock proteins (HSP). Then, HSP increases the levels of transforming growth factor-beta, fibroblast growth factor, epidermal growth factor, platelet-derived growth factor, vascular epithelial growth factor which induce neocollagenesis and neoangiogenesis. Therefore, the thermal energy stored in the vaginal wall induces proliferation of the epithelium which is rich in glycogen, neovascularization and collagen production in the lamina propria.

In this study, evaluation and demonstration of the efficacy of Er:YAG laser for the treatment of atrophic vaginitis in postmenopausal women is intended with Maturation Index (MI), vaginal pH measurement, Female Sexual Function Index (FSFI), Vaginal Health Index (VaHI), Visual Analogue Scale (VAS) and ultrasonographic elastography.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
The participant doesn't know if she receives the sham or laser therapy.
Primary Purpose:
Treatment
Official Title:
Elastographic Improvement of Vaginal Atrophy Treated by Er:YAG Laser
Actual Study Start Date :
Jul 11, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Laser Arm

Non-ablative thermal-only Er:YAG laser (Fotona Dynamis) treatment using R11 and PS03 handpieces

Device: Fotona Dynamis Er:YAG Laser System
The patient receives 2940 nm Er:YAG Laser (XS Dynamis, Fotona, Slovenia) at intervals of 21 days. She receives 3 sessions, in total. Each session consists of application of PS03 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 6 passes followed by R11 handpiece intravaginal with spot size of 7 mm, fluence of 10 j/cm2, frequency of 1.6 Hz and 4-7 pulses per point and 3 passes.

Sham Comparator: Sham Arm

The same procedure is applied but with a sham handpiece.

Device: Sham
Er:YAG laser is applied with sham handpiece.
Other Names:
  • Placebo
  • Outcome Measures

    Primary Outcome Measures

    1. Efficacy: Rate of improvement in vaginal atrophy [6 months]

      Evaluation of the efficacy and safety of vaginal atrophy by using ultrasonographic Elastography

    2. Efficacy:Rate of improvement in sexual function [6 months]

      Evaluation of dyspareunia by Female Sexual Function Index

    3. Efficacy: Rate of improvement in vaginal atrophy [6 months]

      Evaluation of Maturation Index

    4. Efficacy: Rate of improvement in vaginal atrophy [6 months]

      Evaluation of Vaginal Health Index

    5. Efficacy: Rate of improvement in pain [6 months]

      Evaluated by Visual Analogue Scale

    Secondary Outcome Measures

    1. Safety:Incidence and severity of device related Adverse Events [6 months]

      Incidence and severity of device related Adverse Events (i.e., infections, edema, superficial burns, wound dehiscence)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Postmenopausal women with vaginal atrophy symptoms

    • Adult Female, 18 years of age or older

    Exclusion Criteria:
    • Patients with a history of previous vaginal operation,

    • Patients with pelvic organ prolapse

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Istanbul University-Cerrahpaşa Istanbul Turkey 34098
    2 Istanbul University-Cerrahpasa Istanbul Turkey 34450

    Sponsors and Collaborators

    • Istanbul University - Cerrahpasa (IUC)

    Investigators

    • Study Director: Cemal Tamer Erel, Prof., Istanbul University - Cerrahpasa (IUC)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Cemal Tamer Erel, Prof., Istanbul University - Cerrahpasa (IUC)
    ClinicalTrials.gov Identifier:
    NCT06000202
    Other Study ID Numbers:
    • 689852
    First Posted:
    Aug 21, 2023
    Last Update Posted:
    Aug 21, 2023
    Last Verified:
    Jul 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 21, 2023